Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Sunati, Sahoo"'
Autor:
Sunati Sahoo1 sunati.sahoo@utsouthwestern.edu, Krings, Gregor2, Yunn-Yi Chen2, Carter, Jodi M.3, Beiyun Chen3, Hua Guo4, Hanina Hibshoosh4, Reisenbichler, Emily5, Fang Fan6, Shi Wei7,8, Khazai, Laila9, Balassanian, Ronald2, Klein, Molly E.10, Shad, Sonal11, Venters, Sara J.11, Borowsky, Alexander D.12, Symmans, W. Fraser9, Tolgay Ocal, I.13
Publikováno v:
Archives of Pathology & Laboratory Medicine. May2023, Vol. 147 Issue 5, p591-603. 13p. 4 Color Photographs, 1 Diagram, 4 Charts.
Autor:
Lynda B. Bennett, Candace Frerich, Sunati Sahoo, Cheryl Lewis, Indu Raman, Min Xu, Guanchun Chen, Suzanne D. Conzen
Publikováno v:
Cancer Research. 83:P2-21
Invasive lobular breast cancer (ILC) is an understudied subtype of breast cancer with late recurrence, metastasis to serosal surfaces, such as the peritoneum, and dismal long-term outcome. We previously reported better patient outcome in ER+ breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a8b66518adb41d57324fc860938420f
https://doi.org/10.1158/1538-7445.sabcs22-p2-21-08
https://doi.org/10.1158/1538-7445.sabcs22-p2-21-08
Autor:
Sunati Sahoo, Gregor Krings, Yunn-Yi Chen, Jodi M. Carter, Beiyun Chen, Hua Guo, Hanina Hibshoosh, Emily Reisenbichler, Fang Fan, Shi Wei, Laila Khazai, Ronald Balassanian, Molly E. Klein, Sonal Shad, Sara J. Venters, Alexander D. Borowsky, W. Fraser Symmans, I. Tolgay Ocal
Publikováno v:
Archives of Pathology & Laboratory Medicine. 147:591-603
Context.— Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8121605cdd509f66927ad83d4b9e3a04
https://doi.org/10.5858/arpa.2022-0021-ep
https://doi.org/10.5858/arpa.2022-0021-ep
Autor:
B. Bersu Ozcan, Kanwal Merchant, Jordan Goldberg, Zachariah Burns, Sunati Sahoo, Lindsay Compton, Jody C. Hayes, Basak E. Dogan
Publikováno v:
Annals of Breast Surgery. 7:35-35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e86e01fc42ad3f662438a6073f1cd5f
https://doi.org/10.21037/abs-22-23
https://doi.org/10.21037/abs-22-23
Autor:
Mariela Huerta-Rosario, Mariam Mir, Carlos Quispe-Vicuña, Helena Hwang, Venetia Sarode, Yan Peng, Yisheng Fang, Marilyn Leitch, Sunati Sahoo
Publikováno v:
Journal of Clinical Pathology. :jcp-2023
AimsTouch preparation (TP) and frozen section (FS) are the two methods routinely used in the intraoperative evaluation (IOE) of sentinel lymph nodes (SLNs) to detect metastases in patients with breast cancer. Both methods are extremely sensitive and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fb625c02ba549628b992de75f7e2a1a
https://doi.org/10.1136/jcp-2023-208862
https://doi.org/10.1136/jcp-2023-208862
Autor:
Molly Klein, Alexander D. Borowsky, Gregor Krings, Ronald Balassanian, I Tolgay Ocal, Sunati Sahoo, Denise M. Wolf, Kimberley Cole, Shuko Harada, Amy L. Delson, Laura van 't Veer, Kamaljeet Singh, Kimmie Rabe, W. Fraser Symmans, Sara J. Venters, Sonal Shad, Yunn-Yi Chen, Laura J. Esserman, Malini Harigopal, Lamorna Brown-Swigart, Jodi M. Carter, Laila Khazai
Publikováno v:
Cancer Research. 81:PS4-09
Background: I-SPY 2 is a neoadjuvant platform trial open to patients with locally advanced, molecular high-risk breast cancer. In a concerted pursuit of mid-therapy response biomarkers, we evaluated inter-regimen biopsies, to identify patients who ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6186374efd0cdd3401a62dd0031da0e8
https://doi.org/10.1158/1538-7445.sabcs20-ps4-09
https://doi.org/10.1158/1538-7445.sabcs20-ps4-09
Autor:
Sonal Shad, Nola M. Hylton, Alexander D. Borowsky, David C. Newitt, Shuko Harada, Sara J. Venters, Ronald Balassanian, Molly Klein, I Tolgay Ocal, Sunati Sahoo, Wen Li, Kamaljeet Singh, Kimmie Rabe, Amy L. Delson, Laura van 't Veer, Christina Yau, Gregor Krings, W. Fraser Symmans, Natsuko Onishi, Kimberley Cole, Jessica Gibbs, Jodi M. Carter, Laila Khazai, Malini Harigopal, Barbara LeStage, Yunn-Yi Chen, Denise M. Wolf, Sandra Finestone, Laura J. Esserman, Lamorna Brown-Swigart
Publikováno v:
Cancer Research. 81:PS4-10
Background: The I-SPY 2 TRIAL, open to patients with locally advanced, molecular high-risk breast cancer, aims to bring each patient to pathologic complete response (pCR) with a minimum of toxicity. Here we test the hypothesis that imaging (MR volume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5e7aada35080cbe3930b6b957ea2497
https://doi.org/10.1158/1538-7445.sabcs20-ps4-10
https://doi.org/10.1158/1538-7445.sabcs20-ps4-10
Autor:
Cheryl Ewing, Gretchen M. Ahrendt, Anne M. Wallace, Gregor Krings, Helen Krontiras, Christina Yau, Kimberly Cole, Sunati Sahoo, Julie E. Lang, Dina Kokh, Brigid K. Killelea, Akiko Chiba, Tod Tuttle, W. Fraser Symmans, Molly Klein, Arpana Naik, Yunn-Yi Chen, Marie Osdoit, Constantine Godellas, Roshni Rao, Nora Jaskowiak, Laura J. Esserman, Bev Parker, Julia Tchou, Rita A. Mukhtar, Ronald Balassanian, Smita Asare, Jodi M. Carter, M. Catherine Lee, Eleni A. Tousimis, Laila Khazai, Shannon Tierney, Judy C. Boughey, Rachael Lancaster
Publikováno v:
Cancer Research. 80:P3-08
Background: Patients who achieve a pathological complete response (pCR- defined as no invasive cancer) after neoadjuvant chemotherapy (NAC) for breast cancer (BC) have improved outcomes, but there is still controversy about the significance of residu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66b516c77eeb79849992c7472cd2bfb6
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-16
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-16
Autor:
Michelle E. Melisko, Kirsten K. Edmiston, HS Han, W. Fraser Symmans, Gregor Krings, Molly Klein, Rita Nanda, Claudine Isaacs, Rebecca K. Viscusi, Sunati Sahoo, David M. Euhus, Jeffrey B. Matthews, Angela DeMichele, Erica Stringer-Reasor, Qamar J. Khan, Laura J. van't Veer, Tara Sanft, Christina Yau, Donald A. Berry, Richard Schwab, Janice Lu, Jane Perlmutter, A. Jo Chien, Donald W. Northfelt, Anne M. Wallace, Zaha Mitri, Jane L. Meisel, Julie E. Lang, Jodi M. Carter, Lajos Pusztai, Hope S. Rugo, Rachel L. Yung, Erin D. Ellis, Anthony D. Elias, Laila Khazai, Kathy S. Albain, Yunn-Yi Chen, Nola M. Hylton, Amy S. Clark, Laura J. Esserman, Christos Hatzis, Judy C. Boughey, Douglas Yee, Kimberly Cole, Dina Kokh
Publikováno v:
Cancer Research. 80:P2-20
Background: Achieving a pathologic complete response (pCR) has been shown on the patient level to predict excellent long-term event-free survival outcomes. Residual cancer burden (RCB) quantifies the extent of residual disease for patients who did no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53a3c3bbf1436ab8c293f4edb7054a76
https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02
https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02
Autor:
Jane Wei, Jodi M. Carter, Laila Khazai, Laura J. van't Veer, Molly Klein, Gregor Krings, Dina Kokh, Kimberly Cole, Yunn-Yi Chen, Lamorna Brown-Swigart, Ronald Balassanian, Sara J. Venters, Laura J. Esserman, Bev Parker, Amy L. Delson, Christina Yau, Sunati Sahoo, W. Fraser Symmans, Denise M. Wolf
Publikováno v:
Cancer Research. 80:P6-10
Background: The I-SPY 2 TRIAL enrolls women with locally advanced, molecular high-risk breast cancer. An integrated Residual Cancer Burden (iRCB), based on MRI volume change through treatment, is used to predict pathologic complete response (pCR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51b39a13bb371f3d4aaf7b9450c9fdd1
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-02
https://doi.org/10.1158/1538-7445.sabcs19-p6-10-02